Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clofarabine-based conditioning for allogeneic HSCT
NCT00423514Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Nov 2006
- Primary completion
- Jun 2021
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of clofarabine in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), myelodysplastic syndrome (MDS), juvenile myelomonocytic leukemia (JMML), sponsored by Memorial Sloan Kettering Cancer Center. Started Nov 2006; status: completed.
02
Drugs
clofarabine
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)myelodysplastic syndrome (MDS)juvenile myelomonocytic leukemia (JMML)
Beyond the preview
Go deeper on NCT00423514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00423514.